UK "agrees to double" adult ECMO capacity in the face of H1N1 threat
This article was originally published in Clinica
The UK's only provider of adult extracorporeal membrane oxygenation (ECMO) therapy is in discussions with the government over plans by the latter to "double the number of ECMO facilities". Clinica has learnt that an agreement among "all four UK health ministers" to this effect is still "subject to discussions", but the news is a clear acknowledgement of recent evidence of the crucial role that this technology can play in managing the most severe cases of H1N1 infection.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.